INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).

PRNewsWire • Sep 24, 2026

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.

Reuters • Sep 18, 2026

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DR. REDDY'S LABORATORIES (RDY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal righ.

Business Wire • Aug 20, 2026

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happ.

Business Wire • Aug 20, 2026

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 22, 2026, Dr. Reddy's announced its first quart.

Business Wire • Aug 19, 2026

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $RDY #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 22, 2026, Dr. Reddy's reported its first quarter earnings results for fiscal year 2027, r.

Business Wire • Aug 14, 2026

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

GlobeNewsWire • Aug 6, 2026

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.

Business Wire • Aug 4, 2026

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ -- On July 22, 2026, Dr. Reddy's Laboratories (NYSE: RDY) shares fell approximately 9% after the Company reported a Q1 FY27 earnings miss and disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches.

PRNewsWire • Jul 31, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

RDY shares fell approximately 9% after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches. The investigation focuses on the Company's regulatory statements about semaglutide filings and patient safety. RDY shares fell approximately 9% after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches. The investigation focuses on the Company's regulatory statements about semaglutide filings and patient safety.

GlobeNewsWire • Jul 29, 2026